| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2751 |
| Trial ID | NCT05000450 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ALLO-605 |
| Co-treatment | ALLO-647 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma |
| Year | 2021 |
| Country | United States |
| Company sponsor | Allogene Therapeutics |
| Other ID(s) | ALLO-605-201|IGNITE Study |
| Cohort 1 | |||||||||||
|
|||||||||||